| Identification | Back Directory | [Name]
ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- | [CAS]
1049722-30-6 | [Synonyms]
Targapremir-210
ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]-
N-(3-azidopropyl)-4-(4-(6-(4-methylpiperazin-1-yl)-1H,3'H-[2,5'-bibenzo[d]imidazol]-2'-yl)phenoxy)butanamide
N-(3-azidopropyl)-4-[3-[6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenoxy]butanamide | [Molecular Formula]
C32H36N10O2 | [MDL Number]
MFCD28386319 | [MOL File]
1049722-30-6.mol | [Molecular Weight]
592.694 |
| Hazard Information | Back Directory | [Biological Activity]
Targapremir-210 (TGP-210) is a potent and selective miR-210 inhibitor. It can inhibits pre-miR-210 processing with high affinity (Kd~200 nM). | [in vitro]
Targapremir-210 decreases mature miR-210 levels in MDA-MB-231 cells cultured under hypoxic conditions, with an IC 50 of～200 nM.
It (200 nM) induces apoptosis in MDA-MB-231 cells is selective for the hypoxic environment. Targapremir-210 induces apoptosis in cells under hypoxic conditions and does not induce apoptosis in MDA-MB-231 cells cultured in normoxia. | [in vivo]
Targapremir-210 (100 μL of 200 nM; single ip injection) impedes MDA-MB-231 triple negative breast cancer (TNBC) cells proliferation in vivo. It is able to reach the tumor and sustain for the entire 21-day period, and decreases tumor burden in a TNBC mouse model. | [target]
IC50: 200 nM (miR-210, in MDA-MB-231 cells). | [storage]
Store at -20°C |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|